Is Dr Agarwal's Eye overvalued or undervalued?

As of 3 November 2025, Dr Agarwal's Eye has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its financial ratios, which include a PE ratio of 41.01, an EV to EBITDA of 16.78, and a PEG ratio of 1.93. These figures suggest that the stock is trading at a premium compared to its earnings growth potential.
In comparison to its peers, Dr Agarwal's Eye's PE ratio is significantly lower than that of Max Healthcare, which stands at 92.86, indicating that while Dr Agarwal's Eye is expensive, it is not the most overvalued in its sector. Apollo Hospitals, on the other hand, is considered attractive with a PE of 71.5, suggesting that there are more reasonably valued options available in the market. Despite a recent strong performance with a 3.17% return over the past week, the long-term outlook shows a decline of 12.80% year-to-date, reinforcing the notion that the stock may not justify its current price levels.